Skip to main
ATOS

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics Inc is positioned favorably due to its potential for significant upside based on current valuations, which are deemed attractive. The company's development of innovative therapeutics, particularly in breast cancer and COVID-19 treatment, signifies its focus on addressing unmet medical needs, which could drive future growth. Furthermore, the expected clinical milestones and resulting data releases are identified as likely catalysts that could positively influence the stock's performance.

Bears say

Atossa Therapeutics faced a net loss of $8.7 million, translating to an earnings per share (EPS) of $(0.07), which matched the forecasts yet indicated ongoing financial challenges. The company reported consistent losses over successive periods, reinforcing concerns regarding its financial stability amid a demanding clinical development landscape. Additionally, significant risks are identified in clinical trial outcomes, regulatory approval processes, and market commercialization, all of which could adversely impact future liquidity and overall investor confidence in the stock.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.